Medical Affairs is under growing pressure to show strategic value beyond activity counts, and that mandate rests on MSLs engaging the right HCPs at the right time. Most organizations still identify Key Opinion Leaders (KOLs) from a narrow set of signals through publications, trial participation, and manual field intelligence. The result is a compounding problem: the same high-profile KOLs get engaged by every competitor, while rising stars and community influencers go undetected.
The Problem with Traditional Identification
- The same KOLs, every time: Publication- and trial-heavy KOL lists are pulled from the same public databases every company can access, so they surface the same names industry-wide.
- Over-engagement dulls the value: Once every competitor is targeting the same tier-one physicians, each additional MSL visit brings incremental burden and engagement fatigue.
- Rising stars are missed: Early-career HCPs building credibility through advisory boards, CME teaching, or patient advocacy don't show up in a publication-ranked list until it's too late to build an early relationship.
- The real gap is integration, not data: The data that would reveal a richer KOL universe with CRM history, trial site performance, advisory board records already exists inside most pharma companies. It's rarely connected to external sources or to each other.
A Broader, Integrated Framework
The approach brings together nine categories of data: claims, publications, trial registries, Open Payments, HCP affiliations, digital footprint, CME activity, congress/advocacy connections, and internal pharma data. These are resolved to a single HCP identity and scored across dimensions like scientific contribution, clinical activity, and industry relationships.
That composite score sorts HCPs into six segments - Established KOL, Likely KOL, Rising Star, Community Influencer, Digital Opinion Leader, and HCP (Non-KOL), each with a distinct MSL engagement strategy from advisory board investment to long-term relationship-building to non-personal digital outreach.
What This Changes
- A wider contact universe: CME, advocacy, and digital signals surface a meaningfully larger, more diverse set of influential HCPs.
- More defensible prioritization: A transparent, multi-dimensional score holds up to internal scrutiny better than a manually curated list.
- Less over-engagement risk: Spreading engagement across a richer universe reduces KOL fatigue and improves the quality of field interactions.
- Earlier access to emerging leaders: Trajectory analysis on rising stars builds relationships with future thought leaders before competitors do.
What It Takes
The main technical lift is entity resolution by harmonizing the same HCP across NPI numbers, author names, and CRM identifiers before any scoring is possible. Several of the richest sources (patient-level claims, licensed affiliation data, social listening) carry real licensing costs, and Open Payments data in particular has to be used carefully to stay compliant with the voluntary PhRMA Code. Building and maintaining the system takes coordination across Medical Affairs, IT, Compliance, and Commercial. Organizational readiness matters as much as the analytics.
FAQs
